Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pandemic-generated demand behind strong sales of Flexion’s osteoarthritic drug

Flexion became the latest company to report an unexpected boost in sales during the COVID-19 pandemic with second quarter sales for osteoarthritis drug Zilretta that beat consensus estimates by over $5 million.

On Tuesday, Flexion Therapeutics Inc. (NASDAQ:FLXN) closed

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE